1179361-84-2

Usage

Uses

Used in Pharmaceutical Synthesis:
Ethyl 1-amino-1H-imidazole-5-carboxylate is used as a key intermediate for the development of various therapeutic drugs, including antiviral, antibacterial, and antifungal agents. Its unique chemical structure allows for the creation of diverse drug candidates with potential applications in treating a wide range of diseases and infections.
Used in Organic Chemistry:
In the field of organic chemistry, ethyl 1-amino-1H-imidazole-5-carboxylate is utilized as a precursor in the synthesis of various organic compounds. Its reactivity and functional groups make it an important reagent for the preparation of complex organic molecules and advanced materials.
Used in Drug Development:
Ethyl 1-amino-1H-imidazole-5-carboxylate plays a crucial role in drug development, as it can be incorporated into the molecular structures of new pharmaceuticals. Its presence in these compounds can enhance their biological activity, selectivity, and pharmacokinetic properties, leading to more effective and safer medications.
Used in Chemical Synthesis Industry:
As a valuable reagent in the chemical synthesis industry, ethyl 1-amino-1H-imidazole-5-carboxylate is employed in the production of pharmaceutical intermediates and other organic compounds. Its versatility and compatibility with various synthetic routes make it an essential component in the development of novel chemical entities and advanced materials.

Upstream product

• 72804-96-7 O-(diphenylphosphinyl)hydroxylamine 
• 23785-21-9 1H-imidazole-5-carboxylic acid ethyl ester 
• 23785-21-9 ethyl 1H-imidazole-4-carboxylate 

Relevant academic research and scientific papers

ATR INHIBITORS AND USES THEREOF

The present disclosure relates to novel compounds useful as inhibitors of ATR kinase, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.

Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy

There is strong evidence that inhibition of one or more Aldehyde Dehydrogenase 1A (ALDH1A) isoforms may be beneficial in chemotherapy-resistant ovarian cancer and other tumor types. While many previous efforts have focused on development of ALDH1A1 select

IRAK INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for inhibiting one or more interleukin-1 receptor-associated kinases ("IRAK").

HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.

INHIBITORS OF PI3 KINASE

There is provided compounds of formula (I), wherein A1, A4, A4a, A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.